Marcus St John, MD
Interventional Cardiology · Miami, FLNPI 1073510269
Payments from drug & device makers
Across 144 payments — averaging $154.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Circulation Inc$14K
- Abbott$3K
- Boston Scientific$1K
- Medtronic$867
- E.r. Squibb & Sons, L.L.C.$246
- Cardiac Dimensions, Inc.$226
- plus $2K from 26 others
What the payments were for
- Consulting fees$5,32524%
- Speaking & faculty fees$5,87526%
- Travel & lodging$3,87517%
- Food & beverage$7,01832%
- Education$1171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Circulation Inc | 24 | $14,353 |
| Abbott | 33 | $3,167 |
| Boston Scientific | 16 | $1,398 |
| Medtronic(2 entities) | 7 | $867 |
| E.r. Squibb & Sons, L.L.C. | 12 | $246 |
| Cardiac Dimensions, Inc. | 2 | $226 |
| Cleerly, Inc. | 1 | $224 |
| Impulse Dynamics (USA) Inc. | 2 | $195 |
| Atricure, Inc. | 2 | $191 |
| Siemens Medical Solutions USA, Inc. | 1 | $161 |
| Chiesi USA, Inc. | 2 | $138 |
| Penumbra, Inc. | 1 | $126 |
| Novartis | 6 | $108 |
| Pfizer | 5 | $104 |
| AstraZeneca | 1 | $100 |
| Kestra Medical Technology Services, Inc. | 3 | $95 |
| Cardinal Health 200 LLC | 3 | $66 |
| Amgen | 3 | $58 |
| Gilead | 3 | $48 |
| Novo Nordisk | 3 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $37 |
| Edwards Lifesciences | 1 | $31 |
| Terumo Medical Corporation | 1 | $30 |
| Canon Medical Systems USA, Inc. | 1 | $24 |
| Irhythm Technologies, Inc. | 1 | $22 |
| Baxter Healthcare | 1 | $21 |
| Endotronix, Inc. | 1 | $21 |
| Merck | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TherOx DS2 Console$14,026
- Catheter$14,026
- Downstream Cartridge$14,026
- OPTIS$1,165
- Xience V coronary stent system$1,013
- WATCHMAN FLX$760
- OPTIMIZER$356
- WATCHMAN Access System$274
- Indigo$252
- Cleerly Ischemia$224
- Cleerly Labs$224
- Micra$174
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$166
- SYMPLICITY G3$164
- CorPath GRX$161
- GENERAL ULTRASOUND$158
- COBALT DR MRI SURESCAN$136
- CareLink$132
- KENGREAL$120
- NAVITOR$117
How this compares
$22,209 in reported general payments places this provider in the 65th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 250 | $308,485 |
| EntrestoSacubitril/Valsartan | 211 | $291,797 |
| Repatha SureclickEvolocumab | 130 | $134,630 |
| FarxigaDapagliflozin Propanediol | 99 | $131,400 |
| XareltoRivaroxaban | 108 | $116,648 |
| VascepaIcosapent Ethyl | 64 | $45,600 |
| BrilintaTicagrelor | 30 | $36,528 |
| JardianceEmpagliflozin | 24 | $26,716 |
| Praluent PenAlirocumab | 19 | $22,111 |
| Rosuvastatin Calcium | 739 | $9,473 |
| Ezetimibe | 360 | $7,989 |
| Atorvastatin Calcium | 636 | $7,467 |
| Metoprolol Succinate | 502 | $6,403 |
| Telmisartan | 233 | $4,403 |
| Losartan Potassium | 303 | $3,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $104 | $308,485250 claims |
| NovartisEntresto | $108 | $291,797211 claims |
| AstraZenecaFarxiga, Brilinta | $100 | $167,928129 claims |
| Johnson & JohnsonXarelto | $16 | $116,648108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Miami
- Pedro Martinez-ClarkMiami$1.7M
- Rimsky DenisMiami$1.2M
- Eduardo de MarchenaMiami$978K
- Ramon QuesadaMiami$593K
- Mauricio CohenMiami$351K
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.